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ABSTRACT 
Background: The long duration response to levodopa in Parkinson’s disease outlasts the 
elimination of the drug by days to weeks. Though a substantive part of anti-parkinsonian 
motor benefit, it cannot easily be observed. 
Objectives: To infer the magnitude of the long duration response during the first decade of 
Parkinson’s disease and to identify factors that influence it.  
Methods: Serial defined off scores of 24 patients from a longitudinal study of the levodopa 
short duration response were used to establish their rate of motor progression. A line of 
notional untreated disability (as if drug treatment had never been given) with the same 
gradient was the basis for a calculation of the long duration response. Predictors of mean 
long duration response amplitude were identified using a multiple linear regression model.  
Results: Over a mean treatment period of 16.6 ± 4.4 years, the annual progression of motor 
disability was 2.3% of the maximum motor disability. The long duration response composed 
49% of the total levodopa response during the first decade of treatment, and this 
proportion was significantly higher soon after commencing levodopa (p = 0.001). Higher pre-
treatment motor score (r = 0.62) and lower MMSE (r = 0.61) were the main predictors of a 
larger long duration response. There was little correlation between long and short duration 
responses.  
Conclusions: Long duration responses contribute almost half of the total levodopa benefit 
during the first decade of treatment. An appreciation of both long and short duration 
components of drug symptomatic effects is important in clinical trial design to investigate 
possible neuroprotective treatments. 
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INTRODUCTION 
The long duration response (LDR) to levodopa is a motor benefit in a patient with 
Parkinson’s disease (PD) that outlasts the elimination of the drug by days to weeks. Right at 
the beginning of the era of dopaminergic therapy, George Cotzias and his colleagues were 
aware of it. They noted that after prolonged use of D,L-dopa, it took 4 – 14 days for motor 
state to return to baseline when the drug was ceased.1 Two previous levodopa withdrawal 
studies have estimated the LDR response at about one third of the total levodopa 
response.2,3 In the first year of treatment, the majority of motor benefit comes from the 
LDR.4 Drugs other than levodopa, dopamine receptor agonists for instance, have LDRs as 
well.5,6  
The magnitude of the initial levodopa LDR can be estimated by comparing motor disability 
immediately before treatment with when the drug is withheld overnight after weeks to 
months of treatment.7 Thereafter, it is only possible to measure it by prolonged drug 
withholding, impractical because of the difficulties in managing the loss of motor benefit 
and the delay in restoring it. There is uncertainty about the duration of withdrawal needed 
to reveal fully a LDR. LDRs are the ‘dark matter’ of anti-parkinsonian motor benefit, 
substantive but not directly observable. 
Using serial measurements of defined off states in a cohort of PD patients studied 
longitudinally, we devised a method to estimate the LDR. By determining the gradient of 
progression of off scores, it is possible to infer the level of disability if drug treatment had 
never been commenced and to quantify the motor benefit that is not captured by on and off 
phase assessments. 
 
METHODS 
Thirty-four patients with PD were recruited to a longitudinal study of the levodopa motor 
response that began almost 30 years ago. Detailed methodology including entry criteria are 
described in earlier publications.8,9 A modified Webster scale (12 areas of motor function 
scored from 0 to 3 to give a maximum disability score of 36)10 was the chief motor 
assessment. A motor score was recorded before levodopa was started and at optimum 
treatment response during the next 6 months, with the initial drug response defined as the 
difference. At 3-year intervals, a researcher conducted defined off state levodopa test-dose 
assessments on surviving subjects. Levodopa was administered while fasting and after 
withholding of other medication, with the on state defined as the maximum improvement 
over the subsequent 30 – 90 minutes. Amplitude of the short duration response (SDR) was 
calculated as off minus on score. The Folstein Mini Mental State Examination (MMSE)11 was 
performed at each assessment. Patients were classified for the presence of motor 
fluctuations during the first 5 years of levodopa treatment,9 and for motor subtype from 
their modified Webster scale scoring.12 Levodopa equivalent daily doses (LEDD) were 
calculated using standard conversion factors.13 This study has institutional research ethics 
approval. 
Notional untreated disability and LDR calculation 
 
In patients with at least two test-dose assessments, individual gradients of off state motor 
progression were calculated using linear least squares regression. A second line with an 
identical gradient was drawn from each subject’s pre-treatment motor score to represent 
their notional untreated disability (hypothetical progression as if anti-parkinsonian 
treatment had never been commenced). Figure 1 shows these parallel lines on a graph of 
mean results from all participants.  
The LDR amplitude was calculated by subtracting the off score from the notional untreated 
disability score. This was done only for the 3 test-dose assessments performed within the 
first 10 years of treatment because of uncertainty about extrapolation beyond this point. 
The test dose for these assessments was levodopa 200mg/ carbidopa 50mg.  Total levodopa 
response was defined as the sum of the SDR and LDR. 
Statistical methods 
A linear regression model of individual mean LDRs was employed to identify clinical variables that 
predict LDR amplitude. Age of disease onset, pre-treatment motor score, MMSE, LEDD, mean SDR, 
disease phenotype and presence of motor fluctuations were the factors of interest. We used the 
backward elimination method and ANOVA to compare model fit and we tested for interactions using 
product terms. 
We also examined disease progression with a linear mixed-effects regression model of off 
state scores, using treatment duration as a fixed effect. We estimated random effects for 
subjects to account for repeated measures and differing durations of follow-up.  
Descriptive statistics are reported as mean ± standard deviation. Continuous non-parametric 
variables were compared using the Wilcoxon signed rank test. Data analysis was performed using 
R statistical software (R Foundation for Statistical Computing, Vienna, Austria, 2017) and the 
packages nlme14 and ggplot2.15 
 
RESULTS 
Twenty-four patients had two or more test-dose assessments, which allowed estimation of 
a gradient of off state progression. Their mean age at PD diagnosis was 61.1 ± 11.6 years; 
time from diagnosis to treatment initiation was 0.6 ± 2.1 years. The mean follow-up 
duration for these patients was 16.6 ± 4.4 years.  Nine had a tremor-dominant phenotype, 
and 14 developed motor fluctuations. Only 5 patients were still alive at the end of the study 
period. Mean treatment duration for those who had died was 15.2 ± 5.0 years (range 5.2 - 
20.3). At the final assessment of those performed during the first treatment decade, the 
mean MMSE score was 26 ± 5.4 and the mean LEDD was 628 ± 305mg. Although all patients 
began with levodopa monotherapy, by the end of this 10-year period other drugs had also 
been used: bromocriptine (2), pergolide (2), deprenyl (4), benztropine (1).  
Motor Progression & LDR amplitude 
Figure 1 shows the pooled initial and test-dose motor scores for all 34 patients originally 
enrolled in the study, with numbers of survivors at each assessment. The gradient of off 
phase deterioration on this graph is 2.0% p.a. of maximum motor disability. Figure 2 shows 
the 24 individual lines of best fit for progression of motor disability.  According to the linear 
mixed effects regression model, annual progression in disability for this group was 2.3% of 
maximal motor disability.  
Using the notional untreated disease trajectory, we calculated mean LDR amplitude at the 
first defined off state assessment as 4.8 ± 3.6, which is equivalent to 62% of the total motor 
response. The mean of all LDR amplitudes calculated for the first decade of treatment was 
5.1 ± 4.2 or 49% of the total motor response. There was a significant reduction in the 
contribution of the LDR to total motor response between the first and the last of these 
estimations (p = 0.001, r=-0.49). There was no significant change in the absolute magnitude 
of the LDR. 
Predictors of LDR amplitude 
Only higher pre-treatment motor score (r = 0.62, p = 0.001) and lower MMSE (r = 0.61, p = 
0.001) correlated with LDR amplitude. In a two-factor regression model, pre-treatment 
disability and MMSE predicted 65% of the variance in mean LDR. Although mean SDR (Figure 
3) and motor fluctuations did not correlate with mean LDR, their addition as factors 
improved the regression model of mean LDR (four-factor model adjusted R2 = 0.74, F (21,19) 
= 4.50, p = 0.03), and were thus included in the final model (Table 1). LEDD, age at diagnosis 
and disease phenotype were not significant predictors and there were no interactions. 
DISCUSSION 
Overall, the LDR composed about half of the total levodopa motor response, comparable to 
the size of the SDR and somewhat larger than previous estimates. The percentage was 
significantly higher early in the disease course, starting at 62% for the first test-dose 
measurement and falling to 42% by the final reckoning. As shown by the multiple regression 
analysis and Figure 3, there is surprisingly little correlation between the sizes of LDRs and 
SDRs. The strongest predictors of a large LDR were pre-treatment disability and reduced 
MMSE score, each of these accounting for about 38% of the variation of the mean LDR. 
Greater initial motor deficit and early cognitive decline both imply a heavier burden of Lewy 
pathology in the brain, yet these patients appear to have a greater early LDR. Age at 
diagnosis had no significant effect. 
Our method for calculating the LDR takes advantage of longitudinal defined off state 
measures of the SDR. It relies on three important assumptions. First, that disease 
progression is linear during the first part of the disease course. Secondly, that the rate of 
decline is 2-3%. Three other longitudinal studies, though not employing rigorous levodopa 
test-dose methods, produced linear plots of progression over 8-year periods, with estimates 
of annual deterioration of between 1.4% and 3.1%.16-18 Third, that commonly used 
symptomatic treatments do not modify the underlying disease process. The validity of a 
notional untreated disability line that runs from the pre-treatment motor score in parallel to 
the trajectory of the defined off phase scores rests squarely on this last assumption. The 
best interpretation of available evidence is that levodopa, the dominant anti-parkinsonian 
drug in this study, has a powerful but purely symptomatic effect on PD with no influence on 
the underlying rate of progression. 
Large clinical trials of possible neuroprotective agents have struggled to discern 
symptomatic motor benefit from an effect on the natural disease course.19-21 Several LDR 
considerations are relevant. Trial designs have incorporated questionable assumptions 
about wash-in and wash-out times for symptomatic effects.20,21 Wash-in is an estimate of 
the time taken for both SDR and LDR to fully develop. Wash-out, on the other hand, is 
mainly an estimate of time taken for a LDR to decay, since SDRs of most drugs can be 
predicted to follow their pharmacokinetic elimination curve after discontinuation. Another 
impediment to neuroprotective drug trials is the difference in magnitude between 
symptomatic and disease modifying effects. An agent that is capable of completely arresting 
the disease would cause a 2 – 3% deviation from the trajectory of a placebo control group 
over 1 year. A drug that retarded progression by 20% would cause the line to deviate by 
only 0.4% to 0.6% p.a. But the symptomatic effect of dopaminergic therapy runs at around 
22% of the maximum disability score for the combined SDR and LDR. In a clinical trial of less 
than a decade, even modest variability of symptomatic effects may obscure a disease 
modifying one. Such variability could come from standard therapy or from an inherent 
symptomatic effect of a putative neuroprotective agent.  At least the SDR can be measured 
by a defined off phase test dose method. There is no practical way of directly measuring 
variations of a LDR over time. Until a better biomarker for pathological progression in PD is 
found, proof of neuroprotective effect must depend on measurement of the rate of 
deterioration of motor disability scores. Simple, placebo-controlled study designs of long (5 
– 10 years) duration may be the best approach. Standardisation of anti-parkinsonian drug 
therapy and avoidance of delayed drug start or withdrawal protocols should reduce the risk 
of confounding LDR effects. 
Nutt et al. concluded that the presence of a long and a short duration levodopa effect 
implies either two different compartments that take up and release dopamine, or two 
different effector systems for levodopa with different time courses.7 The most plausible 
explanation of a dopaminergic response in the absence of dopaminergic drugs is that the 
separate compartment of dopamine release for the LDR is the surviving nigral neurons. A 
residual population of nigral cells is important, probably essential, to the dopaminergic drug 
response. Roughly 50% can be lost and the dopaminergic nigrostriatal system has sufficient 
functional reserve to forestall motor deficit.22 Thereafter, signs of parkinsonism appear and 
progress up to the point that drug treatment is commenced. But once an LDR is established, 
Figure 1 shows that more than 5 years will pass before the level of pre-treatment disability 
is reached again. Concomitant dopaminergic pharmacological treatment must somehow 
restore the capacity of these neurons to synthesise and release dopamine when short 
duration effects wane or drugs are temporarily withheld. Perhaps an alternative source of 
dopamine receptor stimulation from tablets allows nigral cells temporarily to reduce their 
energy expenditure because of lowered demand on their metabolic or firing states. That the 
LDR is not immediately re-established by levodopa after a short drug holiday implies a 
compensatory mechanism that takes time to recover.23 Levodopa withdrawal studies 
suggest a relationship between the LDR and the number of surviving nigral neurons. There is 
a LDR in advanced PD but it decays more rapidly than in less severely affected patients.24 
The LDR of levodopa can be sustained by the dopamine receptor agonist apomorphine.25 
 
There are some methodological uncertainties in our approach to the LDR. Disease 
progression may not be linear. Most time relationships in the natural world are not linear, 
and there is some evidence that late progression of PD is exponential.26 Notional untreated 
disability is a logical concept, though it is not certain that progression would follow such a 
predictable parallel course without drug treatment. The SDR measures that form the basis 
for the ascertainment of LDR have their own margin of uncertainty. Defined off states at the 
start of the day may incorporate a sleep benefit element. A minority of patients were taking 
dopamine receptor agonists with longer durations of action than levodopa. 
 
Rightly has the main focus of research into PD moved away from established 
pharmacological treatments on to molecular pathophysiology, its patterns of involvement 
beyond the motor system, and the keys that this might hold to modifying disease 
progression. Yet that singular feature of PD, its dopaminergic motor response, remains a 
mysterious thing. We have tried here to show how an appreciation of both long and short 
duration components of the levodopa symptomatic effect is essential to clinical trial design 
to identify neuroprotective drugs. 
 
 
 
 
Figure 1  
Mean modified Webster scores for all participants. Trapezium-ended box: upper pole, pre-
treatment motor score; lower pole, optimum initial treatment response. White rectangular 
boxes: mean levodopa SDR amplitudes. Dashed line of best fit for mean off phase scores. 
Dotted line for notional untreated disease trajectory. Black rectangular boxes: calculated 
LDRs; gray shaded boxes show possible LDRs for later assessments. 
 
 
 
 
 
 
 
 
 
Figure 2.  
Dashed lines of best fit for each subject’s off motor scores. Solid line with gradient of 2.3% 
p.a. obtained from the linear mixed effects regression model of all off scores. The lengths of 
lines are proportional to treatment durations. 
 
 
 
 
 
 
Figure 3. Each data point represents mean SDR and LDR for each subject’s first decade of 
treatment. There is little correlation (r = 0.12, p = 0.58). 95% confidence interval shaded in 
gray.  
 Table 1. Multiple regression factors that predict mean LDR amplitude 
Disease factors b coefficient 95% confidence interval p value 
Pre-treatment motor score  0.67 0.43: 0.91 <.001 
MMSE -0.44 -0.62: -0.27 <.001 
Motor fluctuations 2.86 0.42: 5.30 .024 
Mean SDR amplitude -0.80 -1.38: -0.22 .009 
The adjusted R2 of this model was 0.74  
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